CHRS Stock Recent News

Coherus BioSciences Inc said on Wednesday that the U.S. Food and Drug Administration (FDA) flagged three observations at its partner Shanghai Junshi Biosciences Ltd's manufacturing site in China for its experimental cancer drug.

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2023 Earnings Conference Call May 8, 2023 5:00 PM ET Company Participants Marek Ciszewski - Investor Relations Denny Lanfear - Chief Executive Officer Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - Chief Financial Officer Conference Call Participants Robyn Karnauskas - Truist Securities Salim Syed - Mizuho Mike Nedelcovych - TD Cowen Douglas Tsao - H.C. Wainwright Ash Verma - UBS Chris Schott - JPM Operator Good day and thank you for standing by.

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.75 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $1.24 per share a year ago.

REDWOOD CITY, Calif., May 04, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:

REDWOOD CITY, Calif., May 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced its first quarter 2023 financial results will be released after market close on Monday, May 8, 2023. Starting at 5:00 pm ET on May 8, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.

Coherus Still Looks Good, Multiple Catalysts This Year (Rating Downgrade).

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2022 Earnings Conference Call March 6, 2023 5:00 PM ET Company Participants Marek Ciszewski - SVP, IR Denny Lanfear - CEO Theresa Lavallee - Chief Development Officer Rosh Dias - Chief Medical Officer Paul Reider - Chief Commercial Officer McDavid Stilwell - CFO Conference Call Participants Salim Syed - Mizuho Douglas Tsao - HC Wainwright Chris Schott - JPMorgan Jason Gerberry - Bank of America Ash Verma - UBS Operator Thank you for standing by, and welcome to Coherus Biosciences Fourth Quarter and Fiscal Year 2022 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to SVP, Investor Relations, Marek Ciszewski.

Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 6.25% and 0.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

REDWOOD CITY, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will present at the following investor conferences in March.

REDWOOD CITY, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that its fourth quarter and full year 2022 financial results will be released after market close on Monday, March 6, 2023. Starting at 5:00 pm ET on March 6, 2023, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.